Pfizer drops Xeljanz patent suits
Flowersandtraveling / Shutterstock.com
Pfizer is the latest pharmaceutical company to sign a licensing agreement with the Medicines Patent Pool (MPP) to help increase access to its COVID-19 oral antiviral treatment candidate PAXLOVID (PF-07321332) for low and middle-income countries.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Pfizer, COVID-19, MPP, Charles Gore, Albert Bourla, big pharma